AtomVie opens C$160M radiopharmaceutical manufacturing facility in Canada
The 72,300 square foot facility is the largest single site contract development and manufacturing organisation (CDMO) facility in North America dedicated to radiopharmaceutical development, according to AtomVie.
CANADA—AtomVie Global Radiopharma has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, following an investment of more than C$160 million (US$115.7 million).
The new facility expands the company’s capacity to manufacture radiopharmaceuticals used in targeted cancer therapies and strengthens Hamilton’s position in Canada’s growing radiopharmaceutical sector.
Facility expands manufacturing capacity
The 72,300-square-foot facility is the largest single-site contract development and manufacturing organisation (CDMO) facility in North America dedicated to radiopharmaceutical development, according to AtomVie.
It increases the company’s manufacturing capacity by more than tenfold and is designed to support production ranging from small-scale development batches to high-throughput commercial manufacturing.
The site will support customers throughout the drug development process, from early research and development to commercial production.
It also includes customisable manufacturing space that can be adapted as customers expand their programmes and production requirements.
The facility will integrate with Ontario’s existing radioisotope infrastructure, allowing AtomVie to support both clinical trials and commercial radiopharmaceutical programmes for pharmaceutical companies worldwide.
The expansion follows an announcement by Invest Ontario in December 2025 that AtomVie planned to invest more than C$138 million (US$99.8 million) in a new facility in Hamilton.
The investment was expected to increase the company’s manufacturing capacity by at least tenfold.
Growing radiopharmaceutical demand
The expansion comes as demand for radiopharmaceuticals continues to increase, creating a need for larger and more reliable manufacturing capacity.
AtomVie provides contract development and manufacturing services for companies developing radiopharmaceutical therapies.
As operations expand, the company expects to grow its workforce and is targeting more than 200 employees by the end of 2026.
AtomVie chief executive officer Bruno Paquin said the facility builds on the company’s experience in radiopharmaceutical development and global manufacturing while providing customers with greater production capacity.
“Above all, it advances our purpose of transforming patients’ lives by delivering high-quality radiopharmaceuticals to those who need them, all around the world,” Paquin said.
AtomVie has supported more than 70 clinical development and technology transfer programmes over more than a decade.
During this period, it has manufactured more than 1,000 current good manufacturing practice batches and delivered more than 4,400 cGMP doses to patients in 28 countries across six continents.
Partnerships and expansion
AtomVie board chairman Kevin McNeill said the new facility reflects the work of the company’s employees and the confidence of its partners.
He added that the site provides commercial-scale manufacturing capabilities for companies developing complex radiopharmaceutical therapies.
AtomVie was spun out of the Centre for Probe Development and Commercialisation, a McMaster University-based Centre of Excellence established to strengthen Canada’s capabilities in radiopharmaceutical innovation and manufacturing.
The facility’s opening brought together government representatives, clients, partners and members of the radiopharmaceutical community and included tours of the new site.
The company has also established partnerships with developers of radiopharmaceutical therapies.
In October 2024, Radiopharm Theranostics and AtomVie entered into an agreement to develop and manufacture 177Lu-BetaBart, a radioantibody being developed for the treatment of multiple solid tumors.
Be the first to leave a comment